MY153231A - Diamine derivatives - Google Patents

Diamine derivatives

Info

Publication number
MY153231A
MY153231A MYPI20022307A MYPI20022307A MY153231A MY 153231 A MY153231 A MY 153231A MY PI20022307 A MYPI20022307 A MY PI20022307A MY PI20022307 A MYPI20022307 A MY PI20022307A MY 153231 A MY153231 A MY 153231A
Authority
MY
Malaysia
Prior art keywords
thrombus formation
syndrome
infarction
group
pulmonary
Prior art date
Application number
MYPI20022307A
Other languages
English (en)
Inventor
Toshiharu Ohta
Noriyasu Haginoya
Kenji Yoshikawa
Masatoshi Nagamochi
Syozo Kobayashi
Makoto Ono
Satoshi Komoriya
Toshiharu Yoshino
Kouichi Uoto
Yumi Nakamoto
Hiroyuki Naito
Akiyoshi Mochizuki
Tsutomu Nagata
Hideyuki Kanno
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27482359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY153231(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MY153231A publication Critical patent/MY153231A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI20022307A 2001-06-20 2002-06-19 Diamine derivatives MY153231A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2001187105 2001-06-20
JP2001243046 2001-08-09
JP2001311808 2001-10-09
JP2001398708 2001-12-28
PCT/JP2002/002683 WO2003000657A1 (fr) 2001-06-20 2002-03-20 Derives de diamine

Publications (1)

Publication Number Publication Date
MY153231A true MY153231A (en) 2015-01-29

Family

ID=27482359

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20022307A MY153231A (en) 2001-06-20 2002-06-19 Diamine derivatives

Country Status (12)

Country Link
US (7) US7365205B2 (OSRAM)
EP (1) EP2343290A1 (OSRAM)
AR (1) AR036102A1 (OSRAM)
BE (1) BE2015C046I2 (OSRAM)
CY (2) CY1113054T1 (OSRAM)
FR (1) FR15C0068I2 (OSRAM)
MY (1) MY153231A (OSRAM)
NL (1) NL300760I2 (OSRAM)
PT (1) PT1405852E (OSRAM)
TW (1) TWI298066B (OSRAM)
WO (1) WO2003000657A1 (OSRAM)
ZA (1) ZA200309866B (OSRAM)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI288745B (en) 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
AU2002346300C1 (en) * 2001-06-20 2014-03-06 Daiichi Sankyo Company, Limited Diamine derivatives
WO2003000657A1 (fr) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
JP4331595B2 (ja) * 2001-08-09 2009-09-16 第一三共株式会社 ジアミン誘導体
WO2008011131A2 (en) * 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
JP4109288B2 (ja) * 2002-12-25 2008-07-02 第一三共株式会社 ジアミン誘導体
US7205318B2 (en) * 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
WO2005032490A2 (en) * 2003-10-08 2005-04-14 Bristol-Myers Squibb Company Cyclic diamines and derivatives as factor xa inhibitors
EP2266992A3 (en) 2003-11-12 2011-05-18 Daiichi Sankyo Company, Limited Process for producing thiazole derivative
BRPI0418244A (pt) * 2003-12-29 2007-04-17 Sepracor Inc composto, métodos para aumentar a concentração de d-serina e/ou diminuir a concentração de produtos tóxicos da oxidação de d-serina pela daao em um mamìfero, para tratar a esquizofrenia, para tratar ou prevenir a perda de memória e/ou cognição associadas com o mal de alzheimer, para tratar a ataxia ou para prevenir a perda da função neuronal caracterìstica de doenças neurodegenerativas, para intensificar a aprendizagem, memória e/ou cognição e para tratar dor neuropática, e, composição farmacêutica
TWI350168B (en) * 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
SG163518A1 (en) * 2004-06-24 2010-08-30 Incyte Corp Amido compounds and their use as pharmaceuticals
CA2589565A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2006002361A2 (en) * 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
WO2006012226A2 (en) 2004-06-24 2006-02-02 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
WO2006012227A2 (en) * 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
EP1758882A4 (en) * 2004-06-24 2008-01-23 Incyte Corp AMID COMPOUNDS AND THEIR USE AS MEDICAMENTS
BRPI0514230A (pt) * 2004-08-10 2008-06-03 Incyte Corp compostos de amido e seu uso como produtos farmacêuticos
US7499687B2 (en) * 2004-11-09 2009-03-03 Theta Microelectronics, Inc. Wireless transmitter DC offset recalibration
US8110581B2 (en) 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
US20060122210A1 (en) * 2004-11-18 2006-06-08 Wenqing Yao Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same
MX2007009283A (es) * 2005-02-18 2008-02-19 Arpida Ag Nuevos procesos para la preparacion de un benzofurano.
US8088796B2 (en) 2005-03-31 2012-01-03 Daiichi Sankyo Company, Limited Triamine derivative
AU2006264317B2 (en) 2005-07-06 2012-02-23 Sunovion Pharmaceuticals Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
US7825155B2 (en) 2005-09-14 2010-11-02 Dainippon Sumitomo Pharma Co., Ltd. Oxindole derivative as feeding control agent
EP1925611B1 (en) 2005-09-16 2016-04-13 Daiichi Sankyo Company, Limited Optically active diamine derivative and process for producing the same
CA2621255A1 (en) * 2005-09-21 2007-04-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
EP1957494A2 (en) * 2005-12-05 2008-08-20 Incyte Corporation Lactam compounds and methods of using the same
ES2594156T3 (es) 2006-01-06 2016-12-16 Sunovion Pharmaceuticals Inc. Cicloalquilaminas como inhibidores de la recaptación de monoaminas
CN104276955A (zh) * 2006-01-06 2015-01-14 赛诺维信制药公司 基于四氢萘酮的单胺再摄取抑制剂
WO2007084314A2 (en) * 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
CA2635814A1 (en) * 2006-01-31 2007-08-09 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2007101270A1 (en) * 2006-03-02 2007-09-07 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2007103719A2 (en) * 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
CN103588659A (zh) 2006-03-31 2014-02-19 赛诺维信制药公司 手性酰胺和胺的制备
EP2013163A1 (en) * 2006-05-01 2009-01-14 Incyte Corporation Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
US7838544B2 (en) * 2006-05-17 2010-11-23 Incyte Corporation Heterocyclic inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and methods of using the same
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
EP2062878A4 (en) 2006-08-30 2010-09-08 Shionogi & Co HYDRAZINE AMIDE DERIVATIVE
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
KR20090111322A (ko) * 2007-01-18 2009-10-26 세프라코 아이엔시. 디 아미노산 옥시다제의 억제제
PT2140867T (pt) 2007-03-29 2017-10-04 Daiichi Sankyo Co Ltd Composição farmacêutica
CA2688493C (en) 2007-05-31 2016-04-19 Sepracor Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
GB0721333D0 (en) * 2007-10-31 2007-12-12 Motac Neuroscience Ltd Medicaments
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2010053583A2 (en) * 2008-11-10 2010-05-14 Dana Farber Cancer Institute Small molecule cd4 mimetics and uses thereof
CN102317248A (zh) * 2008-12-12 2012-01-11 第一三共株式会社 光学活性羧酸的生产方法
JP5305421B2 (ja) 2008-12-17 2013-10-02 第一三共株式会社 ジアミン誘導体の製造方法
WO2010082531A1 (ja) 2009-01-13 2010-07-22 第一三共株式会社 活性化血液凝固因子阻害剤
EP2407457B1 (en) * 2009-03-10 2015-04-22 Daiichi Sankyo Company, Limited Process for producing diamine derivative
EP2407450B1 (en) 2009-03-13 2015-04-22 Daiichi Sankyo Company, Limited Method for producing optically active diamine derivative
WO2010131663A1 (ja) * 2009-05-15 2010-11-18 第一三共株式会社 オキサミド誘導体
KR20120037396A (ko) 2009-06-18 2012-04-19 다이이찌 산쿄 가부시키가이샤 용출성이 개선된 의약 조성물
FR2948372B1 (fr) 2009-07-21 2011-07-22 Servier Lab Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
JP5714562B2 (ja) 2010-02-22 2015-05-07 第一三共株式会社 経口用徐放性固形製剤
JP5749247B2 (ja) * 2010-02-22 2015-07-15 第一三共株式会社 経口用徐放性固形製剤
EP2540317A4 (en) * 2010-02-22 2014-04-16 Daiichi Sankyo Co Ltd SOLID PREPARATION WITH DELAYED RELEASE FOR ORAL ADMINISTRATION
EP2548556B1 (en) 2010-03-19 2016-08-10 Daiichi Sankyo Company, Limited Method for improving dissolvability of anticoagulant
CA2793413C (en) 2010-03-19 2015-11-24 Daiichi Sankyo Company, Limited Crystal form of edoxaban tosylate monohydrate and method of producing same
WO2011149110A1 (en) 2010-05-28 2011-12-01 Daiichi Sankyo Company, Limited Novel composition for the prevention and/or treatment of thromboembolism
EP2589590B1 (en) 2010-07-02 2016-12-28 Daiichi Sankyo Company, Limited Process for preparation of optically active diamine derivative salt
HUP1000598A2 (en) 2010-11-05 2012-09-28 Richter Gedeon Nyrt Indole derivatives
CA2824885A1 (en) 2011-01-19 2012-07-26 Bayer Intellectual Property Gmbh Binding proteins to inhibitors of coagulation factors
US9977846B2 (en) 2011-07-08 2018-05-22 Daiichi Sankyo Company, Limited Product quality control method
JPWO2013022059A1 (ja) 2011-08-10 2015-03-05 第一三共株式会社 ジアミン誘導体含有医薬組成物
US20130158069A1 (en) 2011-12-14 2013-06-20 Daiichi Sankyo Company, Limited Preventive and/or therapeutic agent for thromboembolism in thromboembolism patient with severe renal impairment
CN102659757B (zh) * 2012-04-24 2013-11-06 南京药石药物研发有限公司 一种合成5-氯-3-噻吩甲醛的中间体及其制备方法
RU2665372C2 (ru) 2012-09-03 2018-08-29 Дайити Санкио Компани, Лимитед Пероральная фармацевтическая композиция замедленного высвобождения, содержащая гидрохлорид гидроморфона
JP6223452B2 (ja) 2012-09-07 2017-11-01 ノバルティス アーゲー インドールカルボキサミド誘導体およびその使用
HK1215244A1 (zh) 2012-11-23 2016-08-19 Daiichi Sankyo Co., Ltd. 用於制备(1s，4s，5s)-4-溴-6-氧杂二环[3．2．1]辛烷-7-酮的方法
BR112015022191A8 (pt) 2013-03-15 2018-01-23 Celgene Avilomics Res Inc compostos heteroarila e usos dos mesmos
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
TWI602803B (zh) 2013-03-29 2017-10-21 第一三共股份有限公司 光學活性二胺衍生物之製造方法
BR112015019669A2 (pt) * 2013-03-29 2017-07-18 Daiichi Sankyo Co Ltd método de produção de um composto
WO2015028919A1 (en) 2013-08-29 2015-03-05 Daiichi Sankyo Company, Limited Agent for the treatment and prevention of cancer
WO2015150950A1 (en) 2014-03-31 2015-10-08 Daiichi Sankyo Company, Limited Use of a factor xa inhibitor for treating and preventing bleeding events and related disorders in patients having sensitivity to vitamin k antagonists used as anticoagulants
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
WO2016025681A1 (en) 2014-08-13 2016-02-18 The Trustees Of The University Of Pennsylvania Inhibitors of hiv-1 entry and methods of use thereof
CN104529729B (zh) * 2014-12-31 2016-03-30 浙江永太科技股份有限公司 一种2-氟-3-氯苯甲醛的制备方法
TWI571460B (zh) 2016-03-14 2017-02-21 中化合成生技股份有限公司 二胺衍生物之製造方法
WO2018011823A1 (en) 2016-07-13 2018-01-18 Mylan Laboratories Limited Salt of amine-protected (1s,2r,4s)-1,2-amino-n,n-dimethylcyclohexane-4-carboxamide
WO2018069769A1 (en) 2016-10-13 2018-04-19 Daiichi Sankyo Company, Limited Pharmaceutical composition for inhibiting neointima formation of blood vessel
US10301322B2 (en) 2016-12-27 2019-05-28 Apotex Inc. Processes for the preparation of edoxaban and intermediates thereof
EP3592736A1 (en) 2017-03-10 2020-01-15 Rutgers, the State University of New Jersey Indole derivatives as efflux pump inhibitors
GB201807014D0 (en) 2018-04-30 2018-06-13 Univ Leeds Innovations Ltd Factor xlla inhibitors
TWI826474B (zh) 2018-06-27 2023-12-21 日商第一三共股份有限公司 包含二胺衍生物之顆粒劑、以及其用途及製造方法
CN112512591B (zh) 2018-09-26 2024-08-16 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
CN112543771B (zh) 2018-09-30 2023-04-11 江苏豪森药业集团有限公司 抗b7h3抗体-依喜替康类似物偶联物及其医药用途
CN109942600B (zh) * 2019-04-15 2021-08-20 内蒙古京东药业有限公司 一种依度沙班的制备方法
WO2021001728A1 (en) * 2019-07-04 2021-01-07 Glenmark Life Sciences Limited Process for preparation of edoxaban
KR20220034818A (ko) 2019-07-10 2022-03-18 바이엘 악티엔게젤샤프트 2-(페닐이미노)-1,3-티아졸리딘-4-온의 제조 방법
KR102333564B1 (ko) 2019-11-28 2021-12-01 동방에프티엘(주) 광학 활성 다이아민 유도체 및 티아졸 유도체의 생산을 위한 새로운 합성경로
CA3162754A1 (en) 2019-12-12 2021-06-17 Jiangsu Hengrui Medicine Co., Ltd. Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
WO2021147993A1 (zh) 2020-01-22 2021-07-29 江苏恒瑞医药股份有限公司 抗trop-2抗体-依喜替康类似物偶联物及其医药用途
US20230165969A1 (en) 2020-03-25 2023-06-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising antibody drug conjugate and use thereof
KR20220160016A (ko) 2020-03-25 2022-12-05 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-psma 항체-엑사테칸 유사체 접합체 및 그의 의학적 용도
EP4130045A4 (en) 2020-03-25 2023-12-27 Jiangsu Hengrui Pharmaceuticals Co., Ltd. METHOD FOR PREPARING AN ANTIBODY-DRUG CONJUGATE
AU2021289927A1 (en) 2020-06-08 2023-01-19 Systimmune, Inc. Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof
KR20220087933A (ko) 2020-12-18 2022-06-27 엠에프씨 주식회사 디아민 유도체의 제조방법
EP4262760A1 (en) 2020-12-18 2023-10-25 KRKA, d.d., Novo mesto Edoxaban formulation containing no sugar alcohols
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
GB202107722D0 (en) 2021-05-28 2021-07-14 Lunac Therapeutics Ltd Factor XIIA Inhibitors
CA3237844A1 (en) 2021-11-15 2023-05-19 Systimmune, Inc. Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
CN116178251A (zh) * 2021-11-26 2023-05-30 上海汇伦医药股份有限公司 一种依度沙班中间体的制备方法
CN116212044A (zh) 2021-12-03 2023-06-06 成都百利多特生物药业有限责任公司 抗人Trop2抗体-喜树碱类药物偶联物及其医药用途
CN114456194B (zh) * 2021-12-14 2023-07-07 浙江九洲药业股份有限公司 甲苯磺酸艾多沙班的中间体及其制备方法
CN115583900A (zh) * 2022-04-29 2023-01-10 张邦成都生物医药科技有限公司 一种高纯度依度沙班中间体的制备方法
WO2023223346A1 (en) 2022-05-16 2023-11-23 Mylan Laboratories Limited An improved process for the preparation of edoxaban intermediate
CN117752813A (zh) 2022-09-26 2024-03-26 成都百利多特生物药业有限责任公司 抗cd33抗体和抗cd33抗体-药物偶联物及其用途
CN115724792A (zh) * 2022-11-24 2023-03-03 上海柏狮生物科技有限公司 一种依度沙班关键中间体及其合成方法
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3376268A (en) * 1964-02-26 1968-04-02 Monsanto Co Amide-heterocyclic polymers
EP0224566A1 (en) * 1985-06-07 1987-06-10 The Upjohn Company Antiarrhythmic use for aminocycloalkylamides
AU8501291A (en) * 1990-09-10 1992-03-30 Upjohn Company, The Cis-n-(2-aminocyclohexyl)benzamide and their enantiomers as anticonvulsants
IL100576A (en) 1991-01-18 1995-11-27 Eli Lilley And Company Cephalosporin antibiotics
WO1993010022A1 (en) 1991-11-14 1993-05-27 Frutin Bernard D A pressurised container
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
AU6252794A (en) 1993-03-03 1994-09-26 Eli Lilly And Company Balanoids
EP0641770B1 (en) 1993-03-17 1998-05-13 Meiji Seika Kabushiki Kaisha Novel compound with platelet aggregation inhibitor activity
KR970001164B1 (ko) 1993-06-09 1997-01-29 한국과학기술연구원 세팔로스포린계 항생제 및 그의 제조방법
CN1076345C (zh) 1993-10-19 2001-12-19 住友制药株式会社 2,3－二氨基丙酸衍生物
TW270114B (OSRAM) 1993-10-22 1996-02-11 Hoffmann La Roche
US5525042A (en) 1993-11-08 1996-06-11 Clearline Systems, Inc. Liquid pump with compressed gas motive fluid
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
AU6856094A (en) 1994-06-01 1995-12-21 Yamanouchi Pharmaceutical Co., Ltd. Oxadiazole derivative and medicinal composition thereof
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
US5719144A (en) 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
AU5432696A (en) 1995-04-07 1996-10-23 Pharmacopeia, Inc. Carbonyl-piperazinyl and piperidinil compounds which inhibit farnesyl protein transferase
ZA963391B (en) 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
US5726126A (en) 1995-06-02 1998-03-10 American Cyanamid Company 1-(3-heterocyclyphenyl)-S-triazine-2,6,6-oxo or thiotrione herbicidal agents
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
DE19536783A1 (de) 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle Nicotinamid-Chelatbildner vom Typ N¶2¶S¶2¶ für radioaktive Isotope
US5852045A (en) 1995-10-19 1998-12-22 Merck & Co., Inc. Fibrinogen receptor antagonists
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
GB9602294D0 (en) 1996-02-05 1996-04-03 Zeneca Ltd Heterocyclic compounds
JP2002503207A (ja) 1996-04-17 2002-01-29 デュポン ファーマシューティカルズ カンパニー Ｘａ因子阻害剤としてのＮ―（アミジノフェニル）―Ｎ’―（置換）―３Ｈ―２，４―ベンゾジアゼピン―３―オン誘導体
US5668159A (en) 1996-05-08 1997-09-16 The Dupont Merck Pharmaceutical Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists
EP0925286B1 (en) 1996-08-14 2003-01-02 AstraZeneca AB Substituted pyrimidine derivatives and their pharmaceutical use
UA56197C2 (uk) 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
WO1998035956A1 (en) 1997-02-13 1998-08-20 Zeneca Limited Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
IT1291823B1 (it) 1997-04-08 1999-01-21 Menarini Ricerche Spa Composti pseudo-peptidici, loro preparazione ed uso in formulazioni farmaceutiche
EP0986551B1 (en) 1997-05-30 2006-08-02 Takeda Pharmaceutical Company Limited Sulfonamide derivatives, their production and use
US6207679B1 (en) * 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
EP1014962A4 (en) 1997-06-26 2007-06-27 Lilly Co Eli ANTITHROMBOTIC AGENTS
JP2002506462A (ja) 1997-06-26 2002-02-26 イーライ・リリー・アンド・カンパニー 抗血栓物質
US6417200B1 (en) 1997-06-26 2002-07-09 Eli Lilly And Company Antithrombotic agents
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
GB9715895D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
DK1031563T3 (da) 1997-09-30 2006-05-08 Daiichi Seiyaku Co Sulfonylderivater
AR013693A1 (es) 1997-10-23 2001-01-10 Uriach & Cia Sa J Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
US6130349A (en) * 1997-12-19 2000-10-10 The Board Of Trustees Of The Leland Stanford Junior University Catalytic compositions and methods for asymmetric allylic alkylation
EP0937723A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Sulfonamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
EP0937711A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Thiobenzamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
GB9807104D0 (en) 1998-04-02 1998-06-03 Chirotech Technology Ltd The preparation of phosphine ligands
DE19814801A1 (de) * 1998-04-02 1999-10-07 Basf Ag Verfahren zur Herstellung von 1,3,4-trisubstituierten 1,2,4-Triazoliumsalzen
CN1297442A (zh) * 1998-04-21 2001-05-30 杜邦药品公司 用作抗癌剂和抗增殖剂的5－氨基茚并[1,2－c]吡唑－4－酮类化合物
GB9809349D0 (en) 1998-05-02 1998-07-01 Zeneca Ltd Heterocyclic derivatives
GB9809350D0 (en) 1998-05-02 1998-07-01 Zeneca Ltd Novel salt
SK16512000A3 (sk) 1998-05-02 2001-05-10 Astrazeneca Ab Heterocyklické deriváty inhibujúce faktor xa, farmaceutická kompozícia s ich obsahom a ich použitie
EP1090016B1 (en) 1998-06-30 2002-10-30 Chirotech Technology Limited The preparation of arylphosphines
JP2000086659A (ja) 1998-07-14 2000-03-28 Takeda Chem Ind Ltd オクタヒドロピリド［１，２―ａ］ピラジン誘導体
TW434207B (en) 1998-07-24 2001-05-16 Everlight Chem Ind Corp Chiral ligand and method for preparing cyanohydrins from aldehydes
US6303625B1 (en) 1998-07-27 2001-10-16 Ortho-Mcneil Pharmaceutical, Inc. Triazolopyridines for the treatment of thrombosis disorders
US6747023B1 (en) 1998-08-11 2004-06-08 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
US6635657B1 (en) 1998-12-23 2003-10-21 Eli Lilly And Company Aromatic amides
AU2364600A (en) 1998-12-23 2000-07-31 Eli Lilly And Company Heteroroaromatic amides as inhibitor of factor xa
WO2000039111A1 (en) 1998-12-23 2000-07-06 Eli Lilly And Company Antithrombotic amides
DE69915687T2 (de) 1998-12-24 2005-02-10 Eli Lilly And Co., Indianapolis Heterocyclische amide als inhibitoren von faktor xa
GB9902989D0 (en) 1999-02-11 1999-03-31 Zeneca Ltd Heterocyclic derivatives
AU2241400A (en) * 1999-04-06 2000-10-12 Yamanouchi Pharmaceutical Co., Ltd. Novel thiazolobenzoimidazole derivative
JP4390024B2 (ja) 1999-04-23 2009-12-24 アステラス製薬株式会社 新規なジアゼパン誘導体又はその塩
GB9909592D0 (en) 1999-04-26 1999-06-23 Chirotech Technology Ltd Process for the preparation of calanolide precursors
CA2371904A1 (en) 1999-05-24 2000-11-30 Bing-Yan Zhu Inhibitors of factor xa
JP2003502314A (ja) 1999-06-14 2003-01-21 イーライ・リリー・アンド・カンパニー 化合物
AU6448200A (en) * 1999-06-15 2001-01-02 Rhodia Chimie Sulphonylamides and carboxamides and their use in asymmetrical catalysis
GB9914342D0 (en) 1999-06-19 1999-08-18 Zeneca Ltd Compound
JP2001011071A (ja) 1999-06-25 2001-01-16 Mochida Pharmaceut Co Ltd アミノアルキルスルホンアミド誘導体
US6492408B1 (en) 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
GB9917344D0 (en) 1999-07-24 1999-09-22 Zeneca Ltd Novel salt
NZ517603A (en) 1999-09-13 2003-09-26 Dimensional Pharm Inc Azacycloalkanone serine protease inhibitors
EP1216228B1 (en) 1999-09-17 2008-10-29 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
CN1390206A (zh) 1999-09-17 2003-01-08 千嬉药品公司 因子Xa的抑制剂
JP2003514897A (ja) 1999-11-24 2003-04-22 シーオーアール セラピューティクス インコーポレイテッド ベータ−アミノ酸系、アスパラギン酸系およびジアミノプロピオン酸系Ｘａ因子阻害剤
EP1259485B1 (en) 2000-02-29 2005-11-30 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
TWI288745B (en) * 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
CA2413241A1 (en) 2000-06-29 2002-01-10 Bristol-Myers Squibb Pharma Company Thrombin or factor xa inhibitors
US20040067938A1 (en) 2000-09-29 2004-04-08 Penglie Zhang Quaternary amines and related inhibitors of factor xa
EP1322610A2 (en) 2000-09-29 2003-07-02 Millennium Pharmaceuticals, Inc. PIPERAZINE BASED INHIBITORS OF FACTOR Xa
WO2002026734A1 (en) 2000-09-29 2002-04-04 Cor Therapeutics, Inc. PIPERAZIN-2-ONE AMIDES AS INHIBITORS OF FACTOR Xa
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
KR100863923B1 (ko) 2000-11-22 2008-10-17 아스텔라스세이야쿠 가부시키가이샤 치환된 벤젠 유도체 또는 이의 염 및 이를 포함하는 의약 조성물
WO2002060859A2 (en) 2000-12-20 2002-08-08 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
EP1373194B1 (en) 2001-03-30 2007-08-01 Millennium Pharmaceuticals, Inc. BENZAMIDE INHIBITORS OF FACTOR Xa
WO2003000657A1 (fr) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Derives de diamine
AU2002346300C1 (en) * 2001-06-20 2014-03-06 Daiichi Sankyo Company, Limited Diamine derivatives
JP4331595B2 (ja) 2001-08-09 2009-09-16 第一三共株式会社 ジアミン誘導体
AU2002341693B2 (en) 2001-09-21 2008-05-29 Bristol-Myers Squibb Holdings Ireland Unlimited Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
WO2003099276A1 (en) 2002-05-10 2003-12-04 Bristol-Myers Squibb Company 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
TW200510369A (en) * 2002-12-24 2005-03-16 Daiichi Seiyaku Co Novel ethylenediamine derivatives
JP4109288B2 (ja) * 2002-12-25 2008-07-02 第一三共株式会社 ジアミン誘導体

Also Published As

Publication number Publication date
HK1092461A1 (en) 2007-02-09
NL300760I2 (en) 2017-07-20
US20080015215A1 (en) 2008-01-17
CY1113054T1 (el) 2016-04-13
BE2015C046I2 (OSRAM) 2021-07-19
CY2015034I2 (el) 2016-04-13
AR036102A1 (es) 2004-08-11
WO2003000657A1 (fr) 2003-01-03
US20100093785A1 (en) 2010-04-15
US7365205B2 (en) 2008-04-29
PT1405852E (pt) 2012-10-30
FR15C0068I1 (OSRAM) 2015-12-04
EP2343290A1 (en) 2011-07-13
CY2015034I1 (el) 2016-04-13
TWI298066B (en) 2008-06-21
US20090270446A1 (en) 2009-10-29
US20050020645A1 (en) 2005-01-27
FR15C0068I2 (fr) 2016-04-22
US7342014B2 (en) 2008-03-11
US20110312990A1 (en) 2011-12-22
US20110077266A1 (en) 2011-03-31
ZA200309866B (en) 2005-03-30
US20050119486A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
MY153231A (en) Diamine derivatives
MXPA05006989A (es) Derivados de diamina.
BR0210541A (pt) Derivados diamìnicos
WO2003016302A1 (fr) Derives de diamine
RU2345993C2 (ru) ЛАКТАМСОДЕРЖАЩЕЕ СОЕДИНЕНИЕ И ЕГО ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Xa
BR0316585A (pt) Derivados de ácido glioxìlico aril, ariloxi e alquiloxi 1h-indol-3-il substituìdos como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
YU205590A (sh) Amidi imidazo (4,5-b)hinolinoloksi alkanovih kiselina sa poboljšanom rastvorljivošću u vodi i postupak za dobijanje
DK1031563T3 (da) Sulfonylderivater
KR950010895A (ko) 약학 조성물
BR0316574A (pt) Derivados de ácido acético 3-carbonil-1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
DE69818286D1 (de) Pyridylverbindungen und diese enthaltende pharmazeutische zubereitungen
TW200510369A (en) Novel ethylenediamine derivatives
Fareed et al. Small-molecule direct antithrombins: argatroban
CA2343109A1 (en) Thrombin inhibitors
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
EE04564B1 (et) Bifenlamidiini derivaadid, eelravim, vere koagulatsiooniinhibiitor ning proflaktiline ja terapeutiline toimeaine tromboosi v?i emboolia vastu
EA200400545A1 (ru) Новые замещенные 4-фенил-4-[1h-имидазол-2-ил] пиперидиновые производные и их применение в качестве селективных непептидных агонистов дельта-опиоидов
ATE363479T1 (de) Methode zur darstellung von (pyridyl substituierten)methyl-thio-benzimidazol-derivat n
Markwardt et al. The antithrombotic effect of synthetic thrombin inhibitors
EA200400547A1 (ru) Замещенные производные 4-фенил-4-[1h-имидазол-2-ил] пиперидина для снижения ишемического повреждения
ATE35678T1 (de) Vinylcarbonsaeure-derivate und ihre herstellung.
ES2169909T3 (es) 5-hidroximetil-2-aminotetralinas como agentes cardiovasculares.
NO167147C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive tetrahydroisoksazolo(4,5-c)pyridinderivater.
SK96993A3 (en) Agent for production of drug with thrombolytic activity
CA2531980A1 (en) Imide derivatives as therapeutic agents for senile dementia